News
CHMP recommends change to terms of approval for Yescarta for follicular lymphoma. -Kite/Gilead Sciences
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Yescarta (axicabtagene ciloleucel) from Kite Pharma EU B.V.
The CHMP adopted a new indication for the treatment of follicular lymphoma (FL): Yescarta is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
Condition: Follicular + Marginal Zone Lymphoma
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.